Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.9% Higher – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded up 6.9% on Friday . The company traded as high as $3.65 and last traded at $3.6790. 8,986,944 shares changed hands during mid-day trading, a decline of 50% from the average session volume of 17,956,109 shares. The stock had previously closed at $3.44.

Analyst Ratings Changes

A number of brokerages have recently issued reports on RXRX. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Morgan Stanley set a $5.30 target price on Recursion Pharmaceuticals in a research report on Monday, August 17th. Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $8.06.

Recursion Pharmaceuticals Trading Up 5.4%

The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -3.48 and a beta of 1.07. The business’s 50 day moving average price is $3.33 and its 200-day moving average price is $3.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same period in the previous year, the firm earned ($0.41) EPS. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current year.

Insider Activity

In related news, Director Blake Borgeson sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $3.34, for a total transaction of $100,200.00. Following the transaction, the director owned 6,158,287 shares of the company’s stock, valued at approximately $20,568,678.58. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 103,963 shares of company stock worth $368,702. 6.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Recursion Pharmaceuticals by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after buying an additional 7,407,606 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Recursion Pharmaceuticals by 537.3% in the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock valued at $3,367,000 after acquiring an additional 689,903 shares in the last quarter. Lingotto Investment Management LLP increased its position in shares of Recursion Pharmaceuticals by 34.2% during the fourth quarter. Lingotto Investment Management LLP now owns 4,931,057 shares of the company’s stock worth $20,168,000 after purchasing an additional 1,255,980 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Recursion Pharmaceuticals in the 1st quarter valued at $7,370,000. Finally, Norges Bank purchased a new position in Recursion Pharmaceuticals in the 4th quarter valued at $23,473,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.